Union Minister Singh Calls for States to Set Up BioE3 Cells to Strengthen India’s Biotech Tech Future

The BioE3 Policy, approved by Prime Minister Narendra Modi, is part of India’s comprehensive biotech development plan.

In a significant step towards strengthening India's biotechnology sector, Union Minister Dr Jitendra Singh has called on state governments to establish BioE3 Cells, as part of the country’s broader bioeconomy ambitions.

Addressing a recent event, Dr Singh emphasized the critical role these cells will play in driving biomanufacturing initiatives at the state level. He stated that these cells would serve as knowledge hubs, facilitating collaboration between state and national stakeholders and advancing biotechnology efforts across India.

“India’s bioeconomy is poised to grow, and state governments must leverage their unique resources to fuel this growth. From marine and Himalayan resources to region-specific bio-resources, each state has its strengths that can contribute to the larger vision of a Viksit Bharat by 2047,” said Dr Singh.

The BioE3 Policy, approved by PM Modi, is part of India’s comprehensive biotech development plan.

The Union Minister further credited the government’s approach for pushing biotechnology to the forefront of national development. He also highlighted the importance of marine resources, the Himalayan region, and local bio-resources that could help boost India’s biomanufacturing potential.

Central Platforms for Knowledge Exchange

BioE3 Cells will act as vital platforms for policy coordination, knowledge exchange, and the integration of emerging biotechnological practices.

“By establishing a network of BioE3 Cells across the country, the government aims to ensure biomanufacturing practices align with both regional priorities and national goals. These cells will be central to the success of India’s biotechnology future,” Dr Singh explained.

These Cells are envisioned to play a vital role in creating a cohesive approach to biotechnology by fostering collaboration between academia, industry, and entrepreneurs.

Dr Singh also pointed to successful initiatives such as the indigenous DNA vaccine developed during the pandemic, the Nafithromycin antibiotic, and gene therapy trials at CMC Vellore as key examples of India's growing biotechnological capacity.

Dr Singh also highlighted the government’s focus on allocating significant resources to support biomanufacturing initiatives, marking a shift towards prioritizing science and technology over populist measures.